Moreover, inhibition of AR, one of the treatments for PCa, can enhance the expression of NK1R, thereby stimulating the protein kinase C (PKC)/AURKA/N-MYC pathway in PCa cells. The gene discussed is TACR1; the disease is posterior cortical atrophy.